GAIN THERAPEUTICS, INC Adjustments to Additional Paid in Capital, Warrant Issued
GAIN THERAPEUTICS, INC (GANX) reported Adjustments to Additional Paid in Capital, Warrant Issued of $1.03 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-23.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2023-03-23
- GAIN THERAPEUTICS, INC adjustments to additional paid in capital, warrant issued for the quarter ending 2021-12-31 was $172.33K.
- GAIN THERAPEUTICS, INC adjustments to additional paid in capital, warrant issued for the quarter ending 2021-09-30 was $517.00K, a 24.91% increase year-over-year.
- GAIN THERAPEUTICS, INC adjustments to additional paid in capital, warrant issued for the quarter ending 2021-06-30 was $344.67K.
- GAIN THERAPEUTICS, INC adjustments to additional paid in capital, warrant issued for the quarter ending 2020-12-31 was $0.00.
- GAIN THERAPEUTICS, INC adjustments to additional paid in capital, warrant issued for fiscal 2021 was $1.03M, a 149.83% increase from fiscal 2020.
- GAIN THERAPEUTICS, INC adjustments to additional paid in capital, warrant issued for fiscal 2020 was $413.89K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2021-12-31 | $172.33K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $689.33K derived: sum of 2 quarters · filed 2023-03-23 | $1.03M derived: sum of 3 quarters · filed 2023-03-23 | $1.03M 10-K · filed 2023-03-23 |
| 2021-09-30 | $517.00K 10-Q · filed 2022-11-10 | $861.67K derived: sum of 2 quarters · filed 2022-11-10 | $861.67K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $344.67K 10-Q · filed 2022-08-08 | $344.67K 10-Q · filed 2022-08-08 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $413.89K derived: sum of 2 quarters · filed 2022-03-25 | $413.89K 10-K · filed 2022-03-25 | |
| 2020-09-30 | $413.89K 10-Q · filed 2021-11-12 | $413.89K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |